Pitolisant Add-On CPAP Therapy Reduces Excessive Daytime Sleepiness in OSA
Pitolisant may be used as an add-on therapy to continuous positive airway pressure in patients with obstructive sleep apnea suffering from residual diurnal somnolence.
Obstructive Sleep Apnea
Inspire Therapy Approved for Younger Patients With Obstructive Sleep Apnea
The Food and Drug Administration (FDA) has expanded the approval of Inspire therapy (Inspire Medical Systems) to include patients aged 18 to 21 years with moderate to severe obstructive sleep apnea (OSA) who are unable to use continuous positive airway pressure (CPAP). Previously, the therapy was only approved for patients 22 years of age and…
Guidelines Issued for Insomnia, Sleep Apnea in Current, Former Soldiers
VA and DoD joint guideline addresses sleep disorders in military personnel and veterans.
New Drug Product: Sunosi
This slideshow reviews drug information for Sunosi. Click here for the complete Sunosi monograph.
Sunosi Approved for Excessive Daytime Sleepiness With Narcolepsy, OSA
Jazz Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
FDA Accepts Solriamfetol NDA for Narcolepsy-, OSA-Related Sleepiness
Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor.
